The efficacy and tolerability of venetoclax combined with BTK inhibitors have also been established, offering another fixed-duration alternative for patients with CLL [39,85,86,87,88,89,90]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.